Amazingly low Enterprise value for current revenue streams, 231m Barda contract and future revenue.

Not often you find a company where key customer ( US Govt ) funds trials and development and the company maintains all the upside.

I expect institutional support to gain momentum following recent roadshows and a big rerate to follow